<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58533">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01688934</url>
  </required_header>
  <id_info>
    <org_study_id>VND2001</org_study_id>
    <nct_id>NCT01688934</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels
      of V116517 versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Western Ontario and McMaster OA Index (WOMAC) Pain Score</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function Score</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness Score</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory - Short Form (mBPI-SF) Severity of Pain  and Interference of Pain</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental Analgesic Medication Use</measure>
    <time_frame>Over 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>V116517 - 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V116517 50-mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V116517 - 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V116517 30-mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 500-mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V116517 50-mg tablets</intervention_name>
    <description>Taken orally twice daily</description>
    <arm_group_label>V116517 - 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V116517 30-mg tablets</intervention_name>
    <description>Taken orally twice daily</description>
    <arm_group_label>V116517 - 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen 500-mg capsules</intervention_name>
    <description>Taken orally twice daily</description>
    <arm_group_label>Naproxen 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily</description>
    <arm_group_label>V116517 - 50 mg</arm_group_label>
    <arm_group_label>V116517 - 30 mg</arm_group_label>
    <arm_group_label>Naproxen 500 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Subjects with moderate pain due to OA of the knee as their primary pain condition.

          2. Subjects with diagnostic criteria for primary pain condition (American college of
             Rheumatology [ACR] clinical and radiographic criteria):

               -  At least 1 of the following in addition to knee pain: age &gt;50, stiffness &lt;30
                  min, crepitus on active motion, and

               -  Kellgren-Lawrence (K-L) grade â‰¥ 2 radiographic evidence within the past 2 years.

        Key Exclusion Criteria:

          1. Subjects with chronic pain conditions other than OA of the knee as their predominant
             pain condition, including gout, pseudo gout, psoriatic arthritis, active Lyme
             disease, rheumatoid arthritis or any other inflammatory arthritis, fibromyalgia,
             neuropathic pain conditions, bursitis, or acute injury or signs of active infection
             in the target pain area.

          2. Subjects who cannot or will not agree to stop all concomitant analgesic medications,
             apart from specified protocol supplemental analgesic medications.

          3. Subjects with history of seizures within the past 5 years.

          4. Subjects who use opioids more than 4 days per week.

          5. Pain-condition-specific exclusions:

               -  Subjects who received local pain-control procedures, including intra-
                  articular steroid injection in the study knee or intramuscular steroid injection
                  at any site within 6 weeks of entering the study or hyaluronate injection in the
                  study knee within 12 weeks of entering the study.

          6. Subjects who have had arthroscopy on either knee or hip within 6 months of entering
             the study, or open surgery on either knee or hip within 12 months of entering the
             study.

          7. Active-comparator-related exclusions:

               -  Subjects who are allergic to or cannot tolerate naproxen or acetaminophen,
                  including history of NSAID-induced asthma, or nasal polyps;

               -  Subjects with history of bleeding disorders or history of documented
                  gastrointestinal ulcer disease.

        Other protocol specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genova Clinical Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Research Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research East, LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Indiana Center for Clinical Research</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Analgesic Solutions</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte, LLC.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LION Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading, LLP</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
